{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:13Z","timestamp":1790797093790,"version":"4.1.0"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Janssen and Gilead Sci"},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.blre.2019.100635","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T02:05:08Z","timestamp":1572660308000},"page":"100635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections"],"prefix":"10.1016","volume":"40","author":[{"given":"Rossana","family":"Maffei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Maccaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Arletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Fiorcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Benatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.100635_bb0005","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2165\/00003495-200868140-00002","article-title":"Patients at high risk of invasive fungal infections: when and how to treat","volume":"68","author":"R\u00fcping","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2019.100635_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations","volume":"31","author":"Pagano","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100635_bb0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.leu.2403674","article-title":"Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies","volume":"19","author":"M\u00fchlemann","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.100635_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.intimp.2013.05.021","article-title":"Tumor-induced host immunosuppression: special focus on CLL","volume":"17","author":"Cutucache","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2019.100635_bb0025","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100635_bb0030","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.3324\/haematol.2016.151837","article-title":"Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study","volume":"102","author":"Tisi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100635_bb0035","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.3324\/haematol.2015.126698","article-title":"Epidemiology of invasive fungal disease in lymphoproliferative disorders","volume":"100","author":"Teng","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100635_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.blre.2019.100635_bb0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.22094","article-title":"The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia","volume":"107","author":"Francis","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2019.100635_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton\u2019s tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.blre.2019.100635_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11912-017-0620-7","article-title":"Targeting B cell signaling in chronic lymphocytic leukemia","volume":"19","author":"Arnason","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2019.100635_bb0060","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.100635_bb0065","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib--findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2019.100635_bb0070","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-120779","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0075","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100635_bb0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.100635_bb0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100635_bb0095","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100635_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100635_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.100635_bb0110","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0115","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2019.100635_bb0125","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100635_bb0130","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","author":"Bond","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2019.100635_bb0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100635_bb0145","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2018-99-110451","article-title":"Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1\/2 ACE-CL-001 study","volume":"132","author":"Byrd","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0150","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood-2018-99-111919","article-title":"Partial reconstitution of humoral and cellular immunity in patients with chronic lymphocytic leukemia treated with acalabrutinib","volume":"132","author":"Pleyer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0155","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2018-99-110395","article-title":"Acalabrutinib in patients with relapsed\/refractory (R\/R) and high-risk, treatment-naive (TN) chronic lymphocytic leukemia (CLL)","volume":"132","author":"Sun","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0160","first-page":"1593","article-title":"Ibrutinib for chronic lymphocytic leukemia","volume":"374","author":"Ruchlemer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100635_bb0165","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis","volume":"58","author":"Baron","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100635_bb0170","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/cid\/cix1058","article-title":"Invasive fungal sinusitis due to mucor species in a patient on ibrutinib","volume":"66","author":"Serota","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14740\/wjon1099w","article-title":"Cutaneous mucormycosis following a bullous pemphigoid flare in a chronic lymphocytic leukemia patient on ibrutinib","volume":"9","author":"Stein","year":"2018","journal-title":"World J Oncol"},{"key":"10.1016\/j.blre.2019.100635_bb0180","first-page":"1","article-title":"Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?","author":"Abid","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2019.100635_bb0185","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.cmi.2018.01.028","article-title":"Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report","volume":"24","author":"Peri","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2019.100635_bb0190","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","author":"Okamoto","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0195","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.blre.2019.100635_bb0200","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-017-2944-7","article-title":"Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia","volume":"96","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2019.100635_bb0210","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw261","article-title":"Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib","volume":"4","author":"Messina","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hon.2387","article-title":"Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma","volume":"36","author":"Kreiniz","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2019.100635_bb0220","article-title":"Cerebral aspergillosis in a patient on ibrutinib therapy-a predisposition not to overlook","volume":"1078155218788717","author":"Faisal","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.blre.2019.100635_bb0225","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.medmal.2018.01.003","article-title":"Cerebral aspergillosis: an emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?","volume":"48","author":"Gaye","year":"2018","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.blre.2019.100635_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mmcr.2019.02.005","article-title":"Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia","volume":"24","author":"Beresford","year":"2019","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.blre.2019.100635_bb0235","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/10428194.2018.1494271","article-title":"A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses","volume":"60","author":"McCarter","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100635_bb0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000496555","article-title":"The muddied waters of ibrutinib therapy","volume":"141","author":"Schamroth Pravda","year":"2019","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2019.100635_bb0245","first-page":"1","article-title":"High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia","author":"Teh","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100635_bb0250","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/1078155217752078","article-title":"Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia","volume":"25","author":"Stankowicz","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.blre.2019.100635_bb0255","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cmi.2019.01.016","article-title":"Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia","volume":"25","author":"Pouvaret","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2019.100635_bb0260","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V130.Suppl_1.830.830","article-title":"Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center","volume":"130","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0265","first-page":"4323","article-title":"Ibrutinib: a risk factor for invasive fungal infections?","volume":"130","author":"Ruchlemer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0270","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0275","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2018-99-111518","article-title":"Infections in patients with lymphoproliferative diseases treated with target therapy. Italian Multicentric Retrospective Study Seifem 2017","volume":"132","author":"Nadali","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0280","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2019.100635_bb0285","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2019.100635_bb0290","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2018-99-112184","article-title":"Dose-adjusted teddi-R induces durable complete remissions in relapsed and refractory primary CNS lymphoma","volume":"132","author":"Roschewski","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0295","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0300","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.1002\/ajh.24890","article-title":"Ibrutinib-associated Pneumocystis jirovecii pneumonia","volume":"92","author":"Lee","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100635_bb0305","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00265-13","article-title":"X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans infection","volume":"4","author":"Szymczak","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.blre.2019.100635_bb0310","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.blre.2019.100635_bb0315","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/clim.2002.5241","article-title":"Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study","volume":"104","author":"Plebani","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0320","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s12185-009-0322-5","article-title":"Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia","volume":"89","author":"Kanegane","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2019.100635_bb0325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2249.2003.t01-1-02178.x","article-title":"Bruton\u2019s tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function","volume":"133","author":"Gagliardi","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0330","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10875-011-9639-y","article-title":"Dendritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia","volume":"32","author":"Liu","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1073\/pnas.0509784103","article-title":"Regulation of dendritic cell maturation and function by Bruton\u2019s tyrosine kinase via IL-10 and Stat3","volume":"103","author":"Kawakami","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100635_bb0340","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jaci.2013.12.1085","article-title":"Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation","volume":"133","author":"Lougaris","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0345","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/clin.1996.0188","article-title":"Neutropenia in X-linked agammaglobulinemia","volume":"81","author":"Farrar","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.blre.2019.100635_bb0350","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jcp.44.5.388","article-title":"Neutropenia associated with X-linked agammaglobulinaemia","volume":"44","author":"Kozlowski","year":"1991","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2019.100635_bb0355","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2004-01-0207","article-title":"Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses","volume":"104","author":"Mangla","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0360","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2010-04-281170","article-title":"Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia","volume":"117","author":"Fiedler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003940","article-title":"Inflammatory monocytes orchestrate innate antifungal immunity in the lung","volume":"10","author":"Espinosa","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.blre.2019.100635_bb0370","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89890","article-title":"Extrapulmonary Aspergillus infection in patients with CARD9 deficiency","volume":"1","author":"Rieber","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2019.100635_bb0375","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2012-08-450551","article-title":"Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency","volume":"121","author":"Drewniak","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0380","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/cir731","article-title":"Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey","volume":"53","author":"Blumental","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0385","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/MOP.0000000000000031","article-title":"Primary immunodeficiencies underlying fungal infections","volume":"25","author":"Lanternier","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.blre.2019.100635_bb0390","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0395","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/600380","article-title":"Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection","volume":"200","author":"Mircescu","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0400","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood-2009-11-254185","article-title":"Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways","volume":"115","author":"Mueller","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0405","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bph.14090","article-title":"PRN473, an inhibitor of Bruton\u2019s tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling","volume":"175","author":"Herter","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.blre.2019.100635_bb0410","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.1501811","article-title":"Human neutrophils use different mechanisms to kill Aspergillus fumigatus conidia and hyphae: evidence from phagocyte defects","volume":"196","author":"Gazendam","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0415","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ni.2987","article-title":"Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens","volume":"15","author":"Branzk","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0420","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.4049\/jimmunol.178.5.3107","article-title":"Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells","volume":"178","author":"Goodridge","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003446","article-title":"Bruton\u2019s tyrosine kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages","volume":"9","author":"Strijbis","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.blre.2019.100635_bb0430","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMoa0802629","article-title":"Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation","volume":"359","author":"Bochud","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100635_bb0435","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/526500","article-title":"Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis","volume":"197","author":"Carvalho","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2019.100635_bb0440","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.176.6.3635","article-title":"Bruton\u2019s tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production","volume":"176","author":"Horwood","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0445","doi-asserted-by":"crossref","first-page":"240","DOI":"10.15252\/emmm.201404556","article-title":"Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus","volume":"7","author":"Herbst","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.blre.2019.100635_bb0450","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.chom.2015.01.006","article-title":"Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection","volume":"17","author":"Karki","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.blre.2019.100635_bb0455","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2017.01.017","article-title":"Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase","volume":"140","author":"Liu","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0460","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2019.100635_bb0465","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.4049\/jimmunol.164.10.4991","article-title":"Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes","volume":"164","author":"Bouchon","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0470","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/08820139.2011.578270","article-title":"Triggering receptor expressed on myeloid cells-1 (TREM-1) modulates immune responses to Aspergillus fumigatus during fungal asthma in mice","volume":"40","author":"Buckland","year":"2011","journal-title":"Immunol Invest"},{"key":"10.1016\/j.blre.2019.100635_bb0475","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.intimp.2014.09.011","article-title":"Role of TREM-1 in response to Aspergillus fumigatus infection in corneal epithelial cells","volume":"23","author":"Hu","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2019.100635_bb0480","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2010-11-317016","article-title":"Btk is a positive regulator in the TREM-1\/DAP12 signaling pathway","volume":"118","author":"Ormsby","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0485","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.168.3.1362","article-title":"Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus","volume":"168","author":"Bozza","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0490","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.164.4.2021","article-title":"CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection","volume":"164","author":"Traynor","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0495","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1084\/jem.20100906","article-title":"Dectin-1 diversifies Aspergillus fumigatus-specific T cell responses by inhibiting T helper type 1 CD4 T cell differentiation","volume":"208","author":"Rivera","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100635_bb0500","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.blre.2019.100635_bb0505","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1151592","article-title":"A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.blre.2019.100635_bb0510","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.md.0000100046.06009.b0","article-title":"The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients","volume":"82","author":"Winkelstein","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2019.100635_bb0515","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/1074-7613(95)90065-9","article-title":"Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk","volume":"3","author":"Liao","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2019.100635_bb0520","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaci.2005.12.1330","article-title":"Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase","volume":"117","author":"Ferrara","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0525","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2009.07.009","article-title":"Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase","volume":"31","author":"Gomez-Rodriguez","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2019.100635_bb0530","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s10875-014-0110-8","article-title":"Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects","volume":"34","author":"Ghosh","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0535","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/iai.65.2.564-570.1997","article-title":"Th1 and Th2 cytokines in mice with invasive aspergillosis","volume":"65","author":"Cenci","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.blre.2019.100635_bb0540","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2002-01-0265","article-title":"Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies","volume":"100","author":"Hebart","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0545","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.2005.05498.x","article-title":"Cytokines and fungal infections","volume":"129","author":"Antachopoulos","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100635_bb0550","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.leu.2404504","article-title":"Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates","volume":"21","author":"Potenza","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.100635_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149108","article-title":"Mucorales-specific T cells in patients with hematologic malignancies","volume":"11","author":"Potenza","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100635_bb0560","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/02681219880000451","article-title":"Activated lymphocytes reduce adherence of Aspergillus fumigatus","volume":"36","author":"Martins","year":"1998","journal-title":"Med Mycol"},{"key":"10.1016\/j.blre.2019.100635_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074326","article-title":"Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients","volume":"8","author":"Potenza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100635_bb0570","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100635_bb0575","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3389\/fimmu.2017.01939","article-title":"Methods of controlling invasive fungal infections using CD8+ T cells","volume":"8","author":"Kumaresan","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0580","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imm.12953","article-title":"Helper T-cell responses and pulmonary fungal infections","volume":"155","author":"McDermott","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.blre.2019.100635_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087341","article-title":"IL-4 receptor-alpha-dependent control of Cryptococcus neoformans in the early phase of pulmonary infection","volume":"9","author":"Grahnert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100635_bb0590","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/IAI.01172-13","article-title":"Eosinophil deficiency compromises lung defense against Aspergillus fumigatus","volume":"82","author":"Lilly","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.blre.2019.100635_bb0595","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1164\/rccm.201511-2205OC","article-title":"A novel CD4+ T cell-dependent murine model of pneumocystis-driven asthma-like pathology","volume":"194","author":"Eddens","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2019.100635_bb0600","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/eji.200839102","article-title":"IL-17\/Th17 in anti-fungal immunity: what\u2019s new?","volume":"39","author":"Zelante","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0605","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jinf.2016.10.010","article-title":"Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells","volume":"74","author":"Jolink","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.blre.2019.100635_bb0610","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100635_bb0615","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1439-0507.2011.02078.x","article-title":"Innate and adaptive antifungal immune responses: partners on an equal footing","volume":"55","author":"Hamad","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.blre.2019.100635_bb0620","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3324\/haematol.2016.152017","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation","volume":"102","author":"Stadler","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100635_bb0625","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100635_bb0630","doi-asserted-by":"crossref","first-page":"65968","DOI":"10.18632\/oncotarget.11782","article-title":"Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia","volume":"7","author":"Fiorcari","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2019.100635_bb0635","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1074\/jbc.M115.687251","article-title":"Analysis of the effects of the Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fc\u03b3 receptor (Fc\u03b3R) function","volume":"291","author":"Ren","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2019.100635_bb0640","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2019.100635_bb0645","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4049\/jimmunol.181.1.288","article-title":"Dual functions of Bruton\u2019s tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis","volume":"181","author":"Jongstra-Bilen","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0650","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","article-title":"Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages","volume":"100","author":"Borge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100635_bb0655","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1073\/pnas.1424907112","article-title":"Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk","volume":"112","author":"Feng","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100635_bb0660","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0665","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2019.100635_bb0670","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0675","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.100635_bb0680","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","author":"Yin","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100635_bb0685","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0690","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0695","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.100635_bb0700","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100635_bb0710","first-page":"4481","article-title":"Ibrutinib inhibits cGVHD pathogenic pre-germinal center B-cells and follicular helper cells while preserving immune memory and Th1 T-cells","volume":"130","author":"Sahaf","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0715","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2019.100635_bb0720","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2018-99-116444","article-title":"Modulation of T-cell function in the microenvironment of emu-TCL1 CLL bearing mice by Btki appears independent of ITK","volume":"132","author":"Schwarzbich","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0725","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2019.100635_bb0730","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14728214.2018.1479396","article-title":"Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rodgers","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.blre.2019.100635_bb0735","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.100635_bb0740","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bjh.15627","article-title":"Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr\u00f6m macroglobulinaemia on ibrutinib","volume":"185","author":"Cheng","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100635_bb0745","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2011-04-351601","article-title":"The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies","volume":"119","author":"Bergeron","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0750","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2015-12-686873","article-title":"Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia","volume":"127","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0755","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100635_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003434","article-title":"Human genetic susceptibility to invasive aspergillosis","volume":"9","author":"Cunha","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.blre.2019.100635_bb0765","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1080\/10428194.2018.1460474","article-title":"A drug-drug interaction study of ibrutinib with moderate\/strong CYP3A inhibitors in patients with B-cell malignancies","volume":"59","author":"de Jong","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.100635_bb0770","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.419","article-title":"Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling","volume":"100","author":"de Zwart","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2019.100635_bb0775","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/03007995.2018.1502659","article-title":"Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis","volume":"34","author":"Herbrecht","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2019.100635_bb0780","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bmt.2009.39","article-title":"Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients","volume":"44","author":"Mikulska","year":"2009","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:35Z","timestamp":1759436555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19301493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":156,"alternative-id":["S0268960X19301493"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100635","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100635"}}